Recombinant Human Granulocyte/Macrophage Colonystimulating Factor(rhGM-CSF)

Generic Name
Recombinant Human Granulocyte/Macrophage Colonystimulating Factor(rhGM-CSF)
Brand Names
-
Drug Type
-
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Indication

用于:1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染;

2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥;

3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员;

4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少;

5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。

Associated Conditions
-
Associated Therapies
-

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Phase 2
Completed
Conditions
First Posted Date
1999-11-04
Last Posted Date
2019-11-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00001564
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

First Posted Date
1999-11-04
Last Posted Date
2017-07-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT00001512
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation

Phase 3
Completed
Conditions
First Posted Date
1999-11-04
Last Posted Date
2007-09-24
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00001561
Locations
🇺🇸

National Cancer Institute (NCI), Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath